Navigation Links
Liposarcoma -Pipeline Insights, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Liposarcoma -Pipeline Insights, 2014

http://www.reportlinker.com/p02278625/-Liposarcoma--Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Liposarcoma -Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Liposarcoma . This report provides information on the therapeutic development based on the Liposarcoma dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Liposarcoma
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Liposarcoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Liposarcoma and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Liposarcoma
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Liposarcoma pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Liposarcoma Overview
- Liposarcoma Pipeline Therapeutics
- Liposarcoma Therapeutics under Development by Companies
- Liposarcoma Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Liposarcoma Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Liposarcoma Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Liposarcoma Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Liposarcoma – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Liposarcoma – Discontinued Products
- Liposarcoma – Dormant Products
- Companies Involved in Therapeutics Development for Liposarcoma
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Liposarcoma , 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Liposarcoma Assessment by Monotherapy Products
- Liposarcoma Assessment by Combination Products
- Liposarcoma Assessment by Route of Administration
- Liposarcoma Assessment by Stage and Route of Administration
- Liposarcoma Assessment by Molecule Type
- Liposarcoma Assessment by Stage and Molecule Type
- Liposarcoma Therapeutics – Discontinued Products
- Liposarcoma Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Liposarcoma , 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Liposarcoma Assessment by Monotherapy Products
- Liposarcoma Assessment by Combination Products
- Liposarcoma Assessment by Route of Administration
- Liposarcoma Assessment by Stage and Route of Administration
- Liposarcoma Assessment by Molecule Type
- Liposarcoma Assessment by Stage and Molecule Type

To order this report: Liposarcoma -Pipeline Insights, 2014
http://www.reportlinker.com/p02278625/-Liposarcoma--Pipeline-Insights-2014.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>

SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Adenocarcinoma-Pipeline Insights, 2014
2. Lung Disease-Pipeline Insights, 2014
3. Liver Transplantation-Pipeline Insights, 2014
4. Liver Fibrosis-Pipeline Insights, 2014
5. Liver Diseases-Pipeline Insights, 2014
6. Liver Cirrhosis-Pipeline Insights, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for ... by age and sex in these markets. GD epidemiology report is written ... high quality, transparent and market-driven, providing expert analysis of disease trends in ... , Italy , Spain , ...
(Date:2/4/2016)... -- The Senior Care Pharmacy Coalition (SCPC) today commended ... Jason Chaffetz (R-UT) and Ranking Member Elijah ... "Developments in the Prescription Drug Market," to examine ... abusive pharmacy benefit manager (PBM) pricing practices. ... Elijah Cummings (D-MD) are diligent, serious lawmakers committed ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... , ... Health and wellness is a topic that should concern all Americans; ... experiencing an illness. Migraines are a severe form of a headache and often are ... wish the pain on their worst enemy, the feeling can last for many hours ...
(Date:2/5/2016)... NJ (PRWEB) , ... February 05, 2016 , ... ... Primary Care for Patients with Rare Diseases, a continuing medical education (CME) event ... is the first of its kind—and a first for ACCORD, whose mission is ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( ... Career Development event in New York City on Thursday, January 21, 2016. ... of Mediacom, (both alumnus of the varsity Columbia soccer program) spoke at the ...
(Date:2/5/2016)... ... , ... Susan Polk Health Insurance Company recently released a report ... in 2016. To view the report, see below, or visit Susan Polk's blog. ... Obispo seniors who rely on Medicare health insurance and whose monthly income includes social ...
(Date:2/4/2016)... ... February 04, 2016 , ... Dr. Carol Francis ... on February 19-21, 2016, in Southern California . The International Hypnosis Federation 2016 ... 30 professional speakers, including Clinical Psychologist and Hypnotherapist Dr. Carol Francis ...
Breaking Medicine News(10 mins):